, Volume 3, Issue 2, pp 192–206 | Cite as

Contemporary assessment and pharmacotherapy of Tourette syndrome

  • Lawrence Scahill
  • Gerald Erenberg
  • Cheston M. Berlin
  • Cathy Budman
  • Barbara J. Coffey
  • Joseph Jankovic
  • Louise Kiessling
  • Robert A. King
  • Roger Kurlan
  • Anthony Lang
  • Jonathan Mink
  • Tanya Murphy
  • Samual Zinner
  • John Walkup


To develop a guide to clinical assessment and pharmacotherapy for children and adults with Tourette syndrome (TS), we reviewed published literature over the past 25 years to identify original articles and reviews on the assessment and pharmacological treatment of Tourette syndrome, attention—deficit/hyperactivity disorder (ADHD) and obsessive—compulsive disorder (OCD). The literature search also included a survey of reviews published in book chapters. The assessment section was compiled from several reviews. Pharmacological treatments were classified into those with strong empirical support (as evidenced by two positive placebo-controlled studies for tics, OCD, or ADHD in TS samples); modest empirical support (one positive placebo-controlled study), or minimal support (open-label data only). We conclude that accurate diagnosis, including identification of comorbid conditions, is an essential step toward appropriate treatment for patients with TS. In many patients with TS, symptom management requires pharmacotherapy for tics or coexisting conditions. The evidence supporting efficacy and safety for medications used in patients with TS varies. But this evidence offers the best guide to clinical practice.

Key Words

Tourette syndrome ADHD OCD pharmacotherapy 


  1. 1.
    Jankovic J. Tourette’s syndrome.N Engl J Med 345: 1184–1192, 2001.PubMedCrossRefGoogle Scholar
  2. 2.
    Leckman JF. Tourette’s syndrome.Lancet 360: 1577–1586, 2002.PubMedCrossRefGoogle Scholar
  3. 3.
    Piacentini J, Chang S. Behavioral treatments for Tourette syndrome and tic disorders: state of the art.Adv Neurol 85: 319–331, 2001.PubMedGoogle Scholar
  4. 4.
    Craighead WE, Craighead LW. The role of psychotherapy in treating psychiatric disorders.Med Clin North Am 85: 617–629, 2001.PubMedCrossRefGoogle Scholar
  5. 5.
    Foa EB, Franklin ME, Moser J. Context in the clinic: how well do cognitive-behavioral therapies and medications work in combination?Biol Psychiatry 52: 987–997, 2002.PubMedCrossRefGoogle Scholar
  6. 6.
    Wells KC, Pelham WE, Kotkin RA, Hoza B, Abikoff HB, Abramowitz A et al. Psychosocial treatment strategies in the MTA study: rationale, methods, and critical issues in design and implementation.J Abnorm Child Psychol 28: 483–505, 2000.PubMedCrossRefGoogle Scholar
  7. 7.
    Wilhelm S, Deckersbach T, Coffey BJ, Bohne A, Peterson AL, Baer L. Habit reversal versus supportive psychotherapy for Tourette’s disorder: a randomized controlled trial.Am J Psychiatry 160: 1175–1177, 2003.PubMedCrossRefGoogle Scholar
  8. 8.
    Temel Y, Visser-Vandewalle V. Surgery in Tourette syndrome.Mov Disord 19: 3–14, 2004.PubMedCrossRefGoogle Scholar
  9. 9.
    Houeto JL, Karachi C, Mallet L, Pillon B, Yelnik J, Mesnage V et al. Tourette’s syndrome and deep brain stimulation.J Neurol Neurosurg Psychiatry 76: 992–995, 2005.PubMedCrossRefGoogle Scholar
  10. 10.
    Goetz CG, Kompoliti K. Rating scales and quantitative assessment of tics.Adv Neurol 85: 31–42, 2001.PubMedGoogle Scholar
  11. 11.
    Scahill L, King RA, Schultz RT, Leckman JF. Selection and use of diagnostic and clinician rating instruments. In: Tourette’s syndrome: tics, obsessions, compulsions: developmental psychopathology and clinical care (Leckman JF, Cohen DJ, eds), pp 310–324. New York: Wiley, 1999.Google Scholar
  12. 12.
    Leckman JF, Riddle MA, Hardin MT, Ort SI, Swartz KL, Stevenson J, et al. The Yale Global Tic Severity Scale: initial testing of a clinician-rated scale of tic severity.J Am Acad Child Adolesc Psychiatry 28: 566–573, 1989.PubMedCrossRefGoogle Scholar
  13. 13.
    Scahill L, Riddle M, McSwiggin-Hardin M, Ort SI, King RA, Goodman WK et al. Children’s Yale-Brown Obsessive Compulsive Scale: reliability and validity.J Am Acad Child Adolesc Psychiatry 36: 844–852, 1997.PubMedCrossRefGoogle Scholar
  14. 14.
    Kwak C, Dat Vuong K, Jankovic J. Premonitory sensory phenomenon in Tourette’s syndrome.Mov Disord 18: 1530–1533. 2003.PubMedCrossRefGoogle Scholar
  15. 15.
    The Tourette Syndrome Classification Group. Definitions and classifications of tic disorders.Arch Neurol 50: 1013–1016, 1993.CrossRefGoogle Scholar
  16. 16.
    American Psychiatric Association. Diagnostic and statistical manual, fourth edition: treatment revision. Washington, DC: American Psychiatric Association Press, 2000.CrossRefGoogle Scholar
  17. 17.
    Jankovic J. Differential diagnosis and etiology of tics.Adv Neurol 85: 15–29, 2001.PubMedGoogle Scholar
  18. 18.
    Rothenberger A, Kostanecka T, Kinkelbur J, Cohrs S, Woerner W, Hajak G. Sleep and Tourette syndrome.Adv Neurol 85: 245–259, 2001.PubMedGoogle Scholar
  19. 19.
    Kostanecka-Endress T, Banaschewski T, Kinkelbur J, Wullner I, Lichtblau S, Cohrs S et al. Disturbed sleep in children with Tourette syndrome: a polysomnographic study.J Psychosom Res 55: 23–29, 2003.PubMedCrossRefGoogle Scholar
  20. 20.
    Peterson, BS, Staib L, Scahill L, Zhang H, Anderson C, Leckman JF et al. Regional brain and ventricular volumes in Tourette syndrome.Arch Gen Psychiatry 58: 427–440, 2001.PubMedCrossRefGoogle Scholar
  21. 21.
    Singer HS, Szymanski S, Giuliano J, Yokoi F, Dogan AS, Brasic JR et al. Elevated intrasynaptic dopamine release in Tourette’s syndrome measured by PET.Am J Psychiatry 159: 1329–1336. 2002.PubMedCrossRefGoogle Scholar
  22. 22.
    Peterson BS, Thomas P, Kane MJ, Scahill L, Zhang H, Bronen R et al. Basal ganglia volumes in patients with Gilles de la Tourette syndrome.Arch Gen Psychiatry 60: 415–424, 2003.PubMedCrossRefGoogle Scholar
  23. 23.
    Kumar R, Lang AE. Tourette syndrome: secondary tic disorders.Neurol Clin 15: 309–331, 1997.PubMedCrossRefGoogle Scholar
  24. 24.
    Murphy TK, Sajid M, Soto O, Shapira N, Edge P, Yang M. Detecting pediatric autoimmune neuropsychiatric disorders associated with streptococcus in children with obsessive-compulsive disorder and tics.Biol Psychiatry 55: 61–68, 2004.PubMedCrossRefGoogle Scholar
  25. 25.
    Swedo SE. Pediatric autoimmune neuropsychiatric disorders associated with streptococcal infections (PANDAS).Mol Psychiatry 7: S24-S25, 2002.PubMedCrossRefGoogle Scholar
  26. 26.
    Hallett JJ, Kiessling LS. Neuroimmunology of tics and other childhood hyperkinesias.Neurol Clin 15: 333–344, 1997.PubMedCrossRefGoogle Scholar
  27. 27.
    Singer HS, Guiliano JD, Hansen BH, Hallett JJ, Laurino JP, Benson M et al. Antiobodies against human putamen in children with Tourette syndrome.Neurology 50: 1618–1624, 1998.PubMedCrossRefGoogle Scholar
  28. 28.
    Morshed SA, Parveen S, Leckman JF, Mercadante MT, Bittencourt Kiss MH, Miguel EC et al. Antibodies against neural, nuclear, cytoskeletal, and streptococcal epitopes in children and adults with Tourette’s syndrome, Sydenham’s chorea, and autoimmune disorders.Biol Psychiatry 50: 566–577, 2001.PubMedCrossRefGoogle Scholar
  29. 29.
    Loiselle CR, Wendlandt JT, Rohde CA, Singer HS. Antistreptococcal, neuronal, and nuclear antibodies in Tourette syndrome.Pediatr Neurol 28: 119–125, 2003.PubMedCrossRefGoogle Scholar
  30. 30.
    Hallett JJ, Harling-Berg CJ, Knopf PM, Stopa EG, Kiessling LS. Anti-striatal antibodies in Tourette syndrome cause neuronal dysfunction.J Neuroimmunol 111: 195–202, 2000.PubMedCrossRefGoogle Scholar
  31. 31.
    Taylor JR, Morshed SA, Parveen S, Mercadante MT, Scahill L, Peterson BS et al. An animal model of Tourette’s syndrome.Am J Psychiatry 159: 657–660, 2002.PubMedCrossRefGoogle Scholar
  32. 32.
    Church AJ, Dale RC, Lees AJ, Giovannoni G, Robertson MM. Tourette’s syndrome: a cross sectional study to examine the PANDAS hypothesis.J Neurol Neurosurg Psychiatry 74: 602–607. 2003.PubMedCrossRefGoogle Scholar
  33. 33.
    Loiselle CR, Lee O, Moran TH, Singer HS. Striatal microinfusion of Tourette syndrome and PANDAS sera: failure to induce behavioral changes.Mov Disord 19: 390–396, 2004.PubMedCrossRefGoogle Scholar
  34. 34.
    Garvey MA, Perlmutter SJ, Allen AJ, Hamburger S, Lougee L, Leonard HL et al. A pilot study of penicillin prophylaxis for neuropsychiatrie exacerbations triggered by streptococcal infections.Biol Psychiatry 45: 1564–1571, 1999.PubMedCrossRefGoogle Scholar
  35. 35.
    Perlmutter SJ, Leitman SF, Garvey MA, Hamburger S, Feldman E, Leonard HL et al. Therapeutic plasma exchange and intravenous immunoglobulin for obsessive-compulsive disorder and tic disorders in childhood.Lancet 354: 1153–1158, 1999.PubMedCrossRefGoogle Scholar
  36. 36.
    Goodman WK, Price LH, Rasmussen SA, Mazure C, Fleischmann RL, Hill CL et al. The Yale-Brown Obsessive Compulsive Scale. I. Development, use, and reliability.Arch Gen Psychiatry 46: 1006–1011, 1989.PubMedCrossRefGoogle Scholar
  37. 37.
    Goodman WK, Rice LH, Rasmussen SA, Mazure C, Delgado P, Heninger GR et al. The Yale-Brown Obsessive Compulsive Scale. II. Validity.Arch Gen Psychiatry 46: 1012–1016, 1989.PubMedCrossRefGoogle Scholar
  38. 38.
    Cooper J. The Leyton obsessional inventory.Psychol Med 1: 48–64, 1970.PubMedCrossRefGoogle Scholar
  39. 39.
    Berg CJ, Rapoport JL, Flament M. The Leyton obsessional inventory: child version.J Am Acad Child Adolesc Psychiatry 25: 84–91, 1986.CrossRefGoogle Scholar
  40. 40.
    Berg CZ, Whitaker A, Davies M, Flament MF, Rapoport JL. The survey form of the Leyton obsessional inventory: child version. Norms from an epidemiological study.J Am Acad Child Adolesc Psychiatry 27: 759–763, 1988.PubMedCrossRefGoogle Scholar
  41. 41.
    Leckman JF, Walker DE, Goodman WK, Pauls DL, Cohen DJ. “Just right” perceptions associated with compulsive behavior in Tourette’s syndrome.Am J Psychiatry 151: 675–680, 1994.PubMedGoogle Scholar
  42. 42.
    Goyette CH, Conners CK, Ulrich RF. Normative data on revised Conners Parent and Teacher Rating scales.J Abnorm Child Psychol 6: 221–236, 1978.PubMedCrossRefGoogle Scholar
  43. 43.
    DuPaul GJ, Power TJ, McGoey KE, Ikeda MJ, Anastopoulos AD. Reliability and validity of parent and teacher ratings of attention-deficit/hyperactivity disorder symptoms.J Psychoeduc Assess 16: 55–68, 1998.CrossRefGoogle Scholar
  44. 44.
    Swanson J, Lerner M, March J, Gresham FM. Assessment and intervention for attention-deficit/hyperactivity disorder in the schools: lessons from the MTA study.Pediatr Clin North Am 46: 993–1009, 1999.PubMedCrossRefGoogle Scholar
  45. 45.
    MTA Cooperative Group. Multimodal Treatment Study of Children with ADHD: a 14-month randomized clinical trial of treatment strategies for attention-deficit/hyperactivity disorder.Arch Gen Psychiatry 56: 1073, 1999.CrossRefGoogle Scholar
  46. 46.
    Schultz RT, Carter AS, Gladstone M, Scahill L, Leckman JF, Peterson BS et al. Visual-motor integration functioning in children with Tourette syndrome.Neuropsychology 12: 134–145, 1998.PubMedCrossRefGoogle Scholar
  47. 47.
    Como PG. Neuropsychological function in Tourette syndrome.Adv Neurol 85: 103–111, 2001.PubMedGoogle Scholar
  48. 48.
    Jobson KO, Potter WZ. International Psychopharmacology Algorithim Project Report: introduction.Psychopharmacol Bull 31: 457–459, 1995.PubMedGoogle Scholar
  49. 49.
    Ross MS, Moldofsky H. A comparison of pimozide and haloperidol in the treatment of Gilles de la Tourette syndrome.Am J Psychiatry 135: 585–587, 1978.PubMedGoogle Scholar
  50. 50.
    Shapiro AK, Shapiro E. Controlled study of pimozide vs placebo in Tourette’s syndrome.J Am Acad Child Adolesc Psychiatry 23: 161–173, 1984.CrossRefGoogle Scholar
  51. 51.
    Shapiro E, Shapiro AK, Fulop G, Hubbard M, Mandell J, Nordlie J et al. Controlled study of haloperidol, pimozide, and placebo for the treatment of Gilles de la Tourette’s syndrome.Arch Gen Psychiatry 46: 722–730, 1989.PubMedCrossRefGoogle Scholar
  52. 52.
    Sallee FR, Nesbitt L, Jackson C, Sine L, Sethuraman G. Relative efficacy of haloperidol and pimozide in children and adolescents with Tourette’s disorder.Am J Psychiatry 154: 1057–1062, 1997.PubMedGoogle Scholar
  53. 53.
    Kurlan R. Treatment of tics.Neurol Clin North Am 15: 403–409, 1997.Google Scholar
  54. 54.
    Riddle MA, Carlson J. Clinical psychopharmacology for Tourette syndrome and associated disorders.Adv Neurol 85: 343–354, 2001.PubMedGoogle Scholar
  55. 55.
    Scahill L, Chappell PB, King RA, Leckman JF. Pharmacological treatment of tic disorders.Child Adolesc Psychiatr Clin North Am 9: 99–117, 2000.Google Scholar
  56. 56.
    Borison RL, Ang L, Chang S, Dysken M, Comaty JE, Davis JM. New pharmacological approaches in the treatment of Tourette syndrome.Adv Neurol 35: 377–382, 1982.PubMedGoogle Scholar
  57. 57.
    Goetz CG, Tanner CM, Klawans HL. Fluphenazine and multifocal tic disorders.Arch Neurol 41: 271–272, 1984.PubMedCrossRefGoogle Scholar
  58. 58.
    Silay YS, Vuong KD, Jankovic J. The efficacy and safety of fluphenazine in patients with tourette syndrome.Neurology 62: A506, 2004.CrossRefGoogle Scholar
  59. 59.
    Caine ED, Polinsky RJ, Kartzinel R, Ebert MH. The trial use of clozapine for abnormal involuntary disorders.Am J Psychiatry 136: 317–320, 1979.PubMedGoogle Scholar
  60. 60.
    Dion Y, Annable L, Sandor P, Chouinard G. Risperidone in the treatment of tourette syndrome: a double-blind, placebo-controlled trial.J Clin Psychopharmacol 22: 31–39, 2002.PubMedCrossRefGoogle Scholar
  61. 61.
    Scahill L, Leckman JF, Schultz RT, Katsovich L, Peterson BS. A placebo-controlled trial of risperidone in Tourette syndrome.Neurology 60: 1130–1135, 2003.PubMedCrossRefGoogle Scholar
  62. 62.
    Bruggeman R, van der Linden C, Buitelaar JK, Gericke GS, Hawkridge SM, Temlett JA. Risperidone versus pimozide in Tourette’s syndrome: a comparative double-blind parallel group study.J Clin Psychiatry 62: 50–56, 2001.PubMedCrossRefGoogle Scholar
  63. 63.
    Gilbert DL, Batterson JR, Sethuraman G, Sallee FR. Tic reduction with risperidone versus pimozide in a randomized, double-blind, crossover trial.J Am Acad Child Adolesc Psychiatry 43: 206–214, 2004.PubMedCrossRefGoogle Scholar
  64. 64.
    Gaffney GR, Perry PJ, Lund BC, Bever-Stille KA, Arndt S, Kuperman S. Risperidone versus clonidine in the treatment of children and adolescents with Tourette’s syndrome.J Am Acad Child Adolesc Psychiatry 41: 330–336, 2002.PubMedCrossRefGoogle Scholar
  65. 65.
    Budman CL, Gayer A, Lesser M, Shi Q, Bruun RD. An open-label study of the treatment efficacy of olanzapine for Tourette’s disorder.J Clin Psychiatry 62: 290–294, 2001.PubMedCrossRefGoogle Scholar
  66. 66.
    Stamenkovic M, Schindler SD, Aschauser HN, DeZwaan M, Willinger U, Resinger E et al. Effective open-label treatment of Tourette’s disorder with olanzapine.Int Clin Psychopharmacol 15: 23–28, 2000.PubMedCrossRefGoogle Scholar
  67. 67.
    Sallee FR, Kurlan R, Goetz CG, Singer H, Scahill L, Law G et al. Ziprasidone treatment of children and adolescents with Tourette’s syndrome: a pilot study.J Am Acad Child Adolesc Psychiatry 39: 292–299, 2000.PubMedCrossRefGoogle Scholar
  68. 68.
    Mukaddes NM, Abali O. Quetiapine treatment of children and adolescents with Tourette’s disorder.J Child Adolesc Psychopharmacol 13: 295–299, 2003.PubMedCrossRefGoogle Scholar
  69. 69.
    Kastrup A, Schlotter W, Plewnia C, Bartels M. Treatment of tics in Tourette syndrome with aripiprazole.J Clin Psychopharmacol 25: 94–96, 2005.PubMedCrossRefGoogle Scholar
  70. 70.
    Eggers CH, Rothenberger A, Berghaus U. Clinical and neurobiological findings in children suffering from tic disease following treatment with tiapride.Eur Arch Psychiatry Neurol Sci 237: 223–229, 1988.PubMedCrossRefGoogle Scholar
  71. 71.
    Robertson MM, Schnieden V, Lees AJ. Management of Gilles de la Tourette syndrome using sulpiride.Clin Neuropharmacol 3: 229–235, 1990.CrossRefGoogle Scholar
  72. 72.
    Bruun RD. Subtle and unrecognized side effects of neuroleptic treatment in children with Tourette’s disorder.Am J Psychiatry 145: 621–624, 1988.PubMedGoogle Scholar
  73. 73.
    Allison DB, Casey DE. Antipsychotic-induced weight gain: a review of the literature.J Clin Psychiatry 62: 22–31, 2001.PubMedGoogle Scholar
  74. 74.
    Martin A, Scahill L, Anderson GM, Aman M, Arnold LE, Mc-Cracken J et al. Weight and leptin changes among risperidone-treated youths with autism: 6-month prospective data.Am J Psychiatry 161: 1125–1127, 2004.PubMedCrossRefGoogle Scholar
  75. 75.
    Meyer JM, Koro CE. The effects of antipsychotic therapy on serum lipids: a comprehensive review.Schizophr Res 70: 1–17, 2004.PubMedCrossRefGoogle Scholar
  76. 76.
    Singer HS. The treatment of tics.Cur Neurol Neurosci Rep 1: 195–202, 2001.CrossRefGoogle Scholar
  77. 77.
    Desta Z, Kerbusch T, Flockhart DA. Effect of clarithromycin on the pharmacokinetics and pharmacodynamics of pimozide in healthy poor and extensive metabolizers of cytochrome P450 2D6 (CYP2D6).Clin Pharmacol Ther 65: 10–20, 1999.PubMedCrossRefGoogle Scholar
  78. 78.
    Zareba W, Lin DA. Antipsychotic drugs and QT interval prolongation.Psychiatr Q 74: 291–306, 2003.PubMedCrossRefGoogle Scholar
  79. 79.
    U.S. Food and Drug Administration. NDA 20-825 approval letter and labeling for ziprasione. Available at: cder/foi/label, 2001. Accessed March 2004.Google Scholar
  80. 80.
    Blair J, Scahill L, State M, Martin A. Electrocardiographic changes in children and adolescents treated with ziprasidone: a prospective study.J Am Acad Child Adolesc Psychiatry 44: 73–79, 2005.PubMedCrossRefGoogle Scholar
  81. 81.
    Cohen DJ, Young JG, Nathanson JA, Shaywitz BA. Clonidine in Tourette’s syndrome.Lancet 2: 551–553, 1979.PubMedCrossRefGoogle Scholar
  82. 82.
    American Academy of Child and Adolescent Psychiatry. Practice parameters for the assessment and treatment of children, adolescents, and adults with attention-deficit hyperactivity disorder.J Am Acad Child Adolesc Psychiatry 36: 85S-121S, 1997.CrossRefGoogle Scholar
  83. 83.
    Gutgesell H, Atkins D, Barst R, Buck M, Franklin W, Humes R et al. Cardiovascular monitoring of children and adolescents receiving psychotropic drugs: a statement for healthcare professionals from the Committee on Congenital Cardiac Defects, Council on Cardiovascular Disease in the Young, American Heart Association.Circulation 99: 979–982, 1999.PubMedCrossRefGoogle Scholar
  84. 84.
    Leckman JF, Ort S, Caruso KA, Anderson GM, Riddle MA, Cohen DJ. Rebound phenomena in Tourette’s syndrome after abrupt withdrawal of clonidine.Arch Gen Psychiatry 43: 1168–1176, 1986.PubMedCrossRefGoogle Scholar
  85. 85.
    Scahill L, Chappell PB, Kim YS, Schultz RT, Katsovich L, Shepherd E et al. Guanfacine in the treatment of children with tic disorders and ADHD: a placebo-controlled study.Am J Psychiatry 158: 1067–1074, 2001.PubMedCrossRefGoogle Scholar
  86. 86.
    Cummings DD, Singer HS, Krieger M, Miller TL, Mahone EM. Neuropsychiatric effects of guanfacine in children with mild Tourette syndrome: a pilot study.Clin Neuropharmacol 25: 325–332, 2002.PubMedCrossRefGoogle Scholar
  87. 87.
    Kurlan R, Como PG, Deeley C, McDermott M, McDermott MP. A pilot controlled study of fluoxetine for obsessive-compulsive symptoms in children with Tourette’s syndrome.Clin Neuropharmacol 16: 167–172, 1993.PubMedCrossRefGoogle Scholar
  88. 88.
    Scahill L, Riddle MA, King RA, Hardin MT, Rasmusson A, Makuch RW et al. Fluoxetine has no marked effect on tic symptoms in patients with Tourette’s syndrome: a double-blind placebo-controlled study.J Child Adolesc Psychopharmacol 7: 75, 1997.PubMedCrossRefGoogle Scholar
  89. 89.
    Jankovic J, Orman J. Tetrabenazine therapy of dystonia, chorea, tics, and other dyskinesias.Neurology 38: 391–394, 1988.PubMedCrossRefGoogle Scholar
  90. 90.
    Jankovic J, Beach J. Long-term effects of tetrabenazine in hyperkinetic movement disorders.Neurology 48: 358–362, 1997.PubMedCrossRefGoogle Scholar
  91. 91.
    Lipinski JF, Sallee FR, Jackson C, Sethuraman G. Dopamine agonist treatment of Tourette disorder in children: results of an open-label trial of pergolide.Mov Disord 12: 402–407, 1997.PubMedCrossRefGoogle Scholar
  92. 92.
    Gilbert DL, Sethuraman G, Sine L, Peters S, Sallee FR. Tourette’s syndrome improvement with pergolide in a randomized, double-blind, crossover trial.Neurology 54: 1310–1315. 2000.PubMedCrossRefGoogle Scholar
  93. 93.
    Gilbert DL, Dure L, Sethuraman G, Raab D, Lane J, Sallee FR. Tic reduction with pergolide in a randomized controlled trial in children.Neurology 60: 606–611, 2003.PubMedCrossRefGoogle Scholar
  94. 94.
    Goetz CG, Stebbins GT, Thelen JA. Talipexole and adult Gilles de la Tourette’s syndrome: double-blind, placebo-controlled clinical trial.Mov Disord 9: 315–317, 1994.PubMedCrossRefGoogle Scholar
  95. 95.
    Awaad Y. Tics in Tourette syndrome: new treatment options.J Child Neurol 14: 316–319, 1999.PubMedCrossRefGoogle Scholar
  96. 96.
    Jankovic J. Botulinum toxin in the treatment of dystonic tics.Mov Disord 9: 347–349, 1994.PubMedCrossRefGoogle Scholar
  97. 97.
    Kwak CH, Hanna PA, Jankovic J. Botulinum toxin in the treatment of tics.Arch Neurol 57: 1190–1193, 2000.PubMedCrossRefGoogle Scholar
  98. 98.
    Manas C, Andrews D, Sime E, Lang AE. Botulinum toxin for simple motor tics: a randomized, double-blind, controlled clinical trial.Neurology 56: 605–610, 2001.CrossRefGoogle Scholar
  99. 99.
    Porta M, Maggioni G, Ottaviani F, Schindler A. Treatment of phonic tics in patients with Tourette’s syndrome using botulinum toxin type A.Neurol Sci 24: 420–423, 2004.PubMedCrossRefGoogle Scholar
  100. 100.
    Gonce M, Barbeau A. Seven cases of Gilles de la Tourette’s syndrome: partial relief with clonazepam. A pilot study.Can J Neurol Sci 3: 279–283, 1977.Google Scholar
  101. 101.
    Steingard RJ, Goldberg M, Lee D, DeMaso DR. Adjunctive clonazepam treatment of tic symptoms in children with comorbid tic disorders and ADHD.J Am Acad Child Adolesc Psychiatry 33: 394–399, 1994.PubMedCrossRefGoogle Scholar
  102. 102.
    Graae F, Milner J, Rizzotto L, Klein RG. Clonazepam in childhood anxiety disorders.J Am Acad Child Adolesc Psychiatry 33: 372–376, 1994.PubMedCrossRefGoogle Scholar
  103. 103.
    Singer HS, Wendlandt J, Krieger M, Giuliano J. Baclofen treatment in Tourette syndrome: a double-blind, placebo-controlled, crossover trial.Neurology 56: 599–604, 2001.PubMedCrossRefGoogle Scholar
  104. 104.
    Abuzzahab FS, Brown VL. Control of Tourette’s syndrome with topiramate.Am J Psychiatry 158: 968, 2001.PubMedGoogle Scholar
  105. 105.
    Awaad Y, Michon AM, Minarik S. Use of levetiracetam to treat tics in children and adolescents with Tourette syndrome.Mov Disord 20: 714–718, 2005.PubMedCrossRefGoogle Scholar
  106. 106.
    Fraunfelder FW, Fraunfelder FT. Adverse ocular drug reactions recently identified by the National Registry of Drug-Induced Ocular Side Effects.Ophthalmology 111: 1275–1279, 2004.PubMedCrossRefGoogle Scholar
  107. 107.
    Sanberg PR, McConville BJ, Fogelson HM, Manderscheid PZ, Parker KW, Blythe MM et al. Nicotine potentiates the effects of haloperidol in animals and in patients with Tourette syndrome.Biomed Pharmacother 43: 19, 1989.PubMedCrossRefGoogle Scholar
  108. 108.
    McConville BJ, Sanberg PR, Fogelson MH, King J, Cirino P, Parker KW et al. The effects of nicotine plus haloperidol compared to nicotine only and placebo nicotine only in reducing tic severity and frequency in Tourette’s disorder.Biol Psychiatry 15: 832–840, 1992.CrossRefGoogle Scholar
  109. 109.
    Silver AA, Shytle RD, Philipp MK, Wilkinson BJ, McConville B, Sanberg PR. Transdermal nicotine and haloperidol in Tourette’s disorder: a double-blind placebo-controlled study.J Clin Psychiatry 62: 707–714, 2001.PubMedCrossRefGoogle Scholar
  110. 110.
    Shytle RD, Silver AA, Sheehan KH, Sheehan DV, Sanberg PR. Neuronal nicotinic receptor inhibition for treating mood disorders: preliminary controlled evidence with mecamylamine.Depress Anxiety 16: 89–92, 2002.PubMedCrossRefGoogle Scholar
  111. 111.
    Silver AA, Shytle RD, Sheehan KH, Sheehan DV, Ramos A, Sanberg PR. Multicenter, double-blind, placebo-controlled study of mecamylamine monotherapy for Tourette’s disorder.J Am Acad Child Adolesc Psychiatry 40: 1103–1110, 2001.PubMedCrossRefGoogle Scholar
  112. 112.
    Peterson BS, Zhang H, Bondi C, Naftolin F, Leckman JF. A double-blind, placebo-controlled, crossover trial of an antiandrogen in the treatment of Tourette’s syndrome.J Clin Psychopharmacol 18: 324–331, 1998.PubMedCrossRefGoogle Scholar
  113. 113.
    Leonard HL, Swedo SE, Rapoport JL, Koby EV, Lenane MC, Cheslow DL et al. Treatment of obsessive compulsive disorder with clomipramine and desipramine in children and adolescents.Arch Gen Psychiatry 46: 1088–1092, 1989.PubMedCrossRefGoogle Scholar
  114. 114.
    DeVeaugh-Geiss J, Katz R, Landau P, Goodman W, Rasmussen S. Clinical predictors of treatment response in obsessive compulsive disorder: exploratory analyses from multicenter trials of clomipramine.Psychopharmacol Bull 26: 54–59, 1990.PubMedGoogle Scholar
  115. 115.
    DeVeaugh-Geiss J, Moroz G, Biederman J, Cantwell D, Fontaine R, Greist JH et al. Clomipramine hydrochloride in childhood and adolescent obsessive-compulsive disorder: a multicenter trial.J Am Acad Child Adolesc Psychiatry 31: 45–49, 1992.PubMedCrossRefGoogle Scholar
  116. 116.
    Kaplan A, Hollander E. A review of pharmacologic treatments for obsessive-compulsive disorder.Psychiatr Serv 54: 1111–1118. 2003.PubMedCrossRefGoogle Scholar
  117. 117.
    Jenike MA. Clinical practice. Obsessive-compulsive disorder.N Engl J Med 350: 259–265, 2004.PubMedCrossRefGoogle Scholar
  118. 118.
    Montgomery SA, Kasper S, Stein DJ, Bang Hedegaard K, Lemming OM. Citalopram 20 mg, 40 mg and 60 mg are all effective and well tolerated compared with placebo in obsessive-compulsive disorder.Int Clin Psychopharmacol 16: 75–86, 2001.PubMedCrossRefGoogle Scholar
  119. 119.
    March JS, Biederman J, Wolkow R, Safferman A, Mardekian J, Cook EH et al. Sertraline in children and adolescents with obsessive-compulsive disorder: a multicenter randomized controlled trial.JAMA 280: 1752–1156, 1998.PubMedCrossRefGoogle Scholar
  120. 120.
    Geller DA, Hoog SL, Heiligenstein JH, Ricardi RK, Tamura R, Kluszynski S et al. Fluoxetine Pediatric OCD Study Team. Fluoxetine treatment for obsessive-compulsive disorder in children and adolescents: a placebo-controlled clinical trial.J Am Acad Child Adolesc Psychiatry 40: 773–779, 2001.PubMedCrossRefGoogle Scholar
  121. 121.
    Riddle MA, Reeve EA, Yaryura-Tobias JA, Yang HM, Claghom JL, Gaffney G et al. Fluvoxamine for children and adolescents with obsessive-compulsive disorder: a randomized, controlled, multicenter trial.J Am Acad Child Adolesc Psychiatry 40: 222–229, 2001.PubMedCrossRefGoogle Scholar
  122. 122.
    Liebowitz MR, Turner SM, Piacentini J, Beidel DC, Clarvit SR, Davies SO et al. Fluoxetine in children and adolescents with OCD: a placebo-controlled trial.J Am Acad Child Adolesc Psychiatry 41: 1431–1438, 2002.PubMedCrossRefGoogle Scholar
  123. 123.
    Geller DA, Wagner KD, Emslie G, Murphy T, Carpenter DJ, Wetherhold E et al. Paroxetine treatment in children and adolescents with obsessive-compulsive disorder: a randomized, multi-center, double-blind, placebo-controlled trial.J Am Acad Child Adolesc Psychiatry 43: 1387–1396, 2004.PubMedCrossRefGoogle Scholar
  124. 124.
    Pediatric OCD Treatment Study (POTS) Team. Cognitive-behavior therapy, sertraline, and their combination for children and adolescents with obsessive-compulsive disorder: The Pediatric OCD Treatment Study (POTS) randomized controlled trial.JAMA 292: 1969–1976, 2004.CrossRefGoogle Scholar
  125. 125.
    Riddle MA, King RA, Hardin MT, Scahill L, Ort SI, Leckman JF. Behavioral side effects of fluoxetine.J Child Adolesc Psychopharmacol 3: 193–198, 1991.Google Scholar
  126. 126.
    U.S. Food and Drug Administration. Labeling Change Request Letter for Antidepressant Medications. Available at: http://www. labeling, Accessed October 15, 2004.Google Scholar
  127. 127.
    King RA, Riddle MA, Chappell PB, Hardin MT, Anderson GM, Lombroso P et al. Emergence of self-destructive phenomena in children and adolescents during fluoxetine treatment.J Am Acad Child Adolesc Psychiatry 30: 179–186, 1991.PubMedCrossRefGoogle Scholar
  128. 128.
    Oesterheld JR. Erythromycin and clomipramine: noncompetitive inhibition of demethylation.J Child Adolesc Psychopharmacol 6: 211–213, 1996.PubMedCrossRefGoogle Scholar
  129. 129.
    Rosenbaum JF, Fava M, Pava JA, McCarthy MK, Steingard RJ, Bouffides E. Anger attacks in unipolar depression. Part 2: Neuroendocrine correlates and changes following fluoxetine treatment.Am J Psychiatry 150: 1164–1168, 1993.PubMedGoogle Scholar
  130. 130.
    Hollander E, Bienstock CA, Koran LM, Pallanti S, Marazziti D, Rasmussen SA, et al. Refractory obsessive-compulsive disorder: state-of-the-art treatment.J Clin Psychiatry 63: 20–29, 2002.PubMedGoogle Scholar
  131. 131.
    Varley CK. Sudden death related to selected tricyclic antidepressants in children: epidemiology, mechanisms and clinical implications.Paediatr Drugs 3: 613–627, 2001.PubMedCrossRefGoogle Scholar
  132. 132.
    Expert Consensus Panel for Obsessive-Compulsive Disorder. Treatment of obsessive-compulsive disorder.J Clin Psychiatry 58: 2–72, 1997.Google Scholar
  133. 133.
    Wameke LB. The use of intravenous chlorimipramine in the treatment of obsessive compulsive disorder.Can J Psychiatry 29: 135–141, 1984.Google Scholar
  134. 134.
    Koran LM, Pallanti S, Paiva RS, Quercioli L. Pulse loading versus gradual dosing of intravenous clomipramine in obsessive-compulsive disorder.Eur Neuropsychopharmacol 8: 121–126, 1998.PubMedCrossRefGoogle Scholar
  135. 135.
    Sallee FR, Koran LM, Pallanti S, Carson SW, Sethuraman G. Intravenous clomipramine challenge in obsessive-compulsive disorder: predicting response to oral therapy at eight weeks.Biol Psychiatry 44: 220–227, 1998.PubMedCrossRefGoogle Scholar
  136. 136.
    Greenhill LL, Abikoff HB, Arnold LE, Cantwell DP, Conners CK, Elliott G et al. Medication treatment strategies in the MTA study: relevance to clinicians and researchers.J Am Acad Child Adolesc Psychiatry 35: 1304–1313, 1996.PubMedCrossRefGoogle Scholar
  137. 137.
    Elia J, Borcherding BG, Rapoport JL, Keysor CS. Methylphenidate and dextroamphetamine treatments of hyperactivity: are there true non-responders?Psychiatr Res 36: 141–155, 1991.CrossRefGoogle Scholar
  138. 138.
    Erenberg G, Cruse RP, Rothner AD. Gilles de la Tourette’s syndrome: effects of stimulant drugs.Neurology 35: 1346–1348. 1985.PubMedCrossRefGoogle Scholar
  139. 139.
    Golden GS. Gilles de la Tourette’s syndrome following methyl-phenidate administration.Dev Med Child Neurol 16: 76–78, 1974.PubMedCrossRefGoogle Scholar
  140. 140.
    Lowe TL, Cohen DJ, Detlor J, Kremenitzer MW, Shaywitz BA. Stimulant medications precipitate Tourette’s syndrome.JAMA 26: 1729–1731, 1992.Google Scholar
  141. 141.
    Lipkin PH, Goldstein IJ, Adesman AR. Tics and dyskinesias associated with stimulant treatment in attention-deficit hyperactivity disorder.Arch Pediatr Adolesc Med 148: 859–861, 1994.PubMedCrossRefGoogle Scholar
  142. 142.
    Riddle MA, Lynch KA, Scahill L. Methylphenidate discontinuation during long-term treatment of children with Tourette’s disorder and attention deficit hyperactivity disorder: a pilot study.J Child Adolesc Psychopharmacol 5: 205–214, 1995.CrossRefGoogle Scholar
  143. 143.
    Varley CK, Vincent J, Varley P, Calderon R. Emergence of tics in children with attention deficit hyperactivity disorder treated with stimulant medications.Comp Psychiatry 42: 228–233, 2001.CrossRefGoogle Scholar
  144. 144.
    Barkley RA, McMurray MB, Edelbrock CS, Robbins K. Side effects of methylphenidate in children with attention deficit hyperactivity disorder: a systemic, placebo-controlled evaluation.Pediatrics 86: 184–192, 1992.Google Scholar
  145. 145.
    Borcherding BG, Keysor CS, Rapoport JL, Elia J, Amass J. Motor/vocal tics and compulsive behaviors on stimulant drugs: is there a common vulnerability?Psychiatry Res 33: 83–94, 1990.PubMedCrossRefGoogle Scholar
  146. 146.
    Castellanos FX, Geidd JN, Elia J. Controlled stimulant treatment of ADHD and comorbid Tourette’s syndrome: effects of stimulant and dose.J Am Acad Child Adolesc Psychiatry 36: 589–596, 1997.PubMedCrossRefGoogle Scholar
  147. 147.
    Gadow KD, Sverd J, Sprafkin J, Nolan EE, Ezor SN. Efficacy of methylphenidate for attention-deficit hyperactivity disorder in children with tic disorder.Arch Gen Psychiatry 52: 444–455. 1995.PubMedCrossRefGoogle Scholar
  148. 148.
    Tourette Syndrome Study Group. Treatment of ADHD in children with tics: a randomized controlled trial.Neurology 58: 527–536, 2002.CrossRefGoogle Scholar
  149. 149.
    Gadow KD, Sverd J, Sprafkin J, Nolan EE, Grossman S. Long-term methylphenidate therapy in children with comorbid attention-deficit hyperactivity dsorder and chronic multiple tic disorder.Arch Gen Psychiatry 56: 330–336, 1999.PubMedCrossRefGoogle Scholar
  150. 150.
    Law SF, Schachar RJ. Do typical clinical doses of methylphenidate cause tics in children treated for attention-deficit hyperactivity disorder?J Am Acad Child Adolesc Psychiatry 38: 944–951. 1999.PubMedCrossRefGoogle Scholar
  151. 151.
    Biederman J, Baldessarini RJ, Wright V, Knee D, Harmatz JS. A double-blind placebo controlled study of desipramine in the treatment of ADD. I. Efficacy.J Am Acad Child Adolesc Psychiatry 28: 777–784, 1989.PubMedCrossRefGoogle Scholar
  152. 152.
    Singer H, Brown J, Quaskey S, Rosenberg LA, Mellits ED, Denckla MB. The treatment of attention-deficit hyperactivity disorder in Tourette’s syndrome: a double-blind placebo-controlled study with clonidine and desipramine.Pediatrics 95: 74–81, 1995.PubMedGoogle Scholar
  153. 153.
    Spencer T, Biederman J, Coffey B, Geller D, Crawford M, Bearman SK et al. A double-blind comparison of desipramine and placebo in children and adolescents with chronic tic disorder and comorbid attention-deficit/hyperactivity disorder.Arch Gen Psychiatry 59: 649–656, 2002.PubMedCrossRefGoogle Scholar
  154. 154.
    Riddle MA, Geller B, Ryan N. Another sudden death in a child treated with desipramine.J Am Acad Child Adolesc Psychiatry 32: 792–797, 1993.PubMedCrossRefGoogle Scholar
  155. 155.
    Barrickman L, Perry P, Allen A, Kuperman S, Arndt S, Herrmann K, et al. Buproprion versus methylphenidate in the treatment of attention-deficit hyperactivity disorder.J Am Acad Child Adolesc Psychiatry 34: 649–657, 1995.PubMedCrossRefGoogle Scholar
  156. 156.
    Casat CD, Pleasants DZ, Van Wyck Fleet J. A double-blind trial of bupropion in children with attention deficit disorder.Psychopharmacol Bull 23: 120–122, 1987.PubMedGoogle Scholar
  157. 157.
    Casat CD, Pleasants DZ, Schroeder DH, Parler DW. Bupropion in children with attention deficit disorder.Psychopharmacol Bull 25: 198–201, 1989.PubMedGoogle Scholar
  158. 158.
    Conners CK, Casat CD, Gualtieri CT, Weller E, Reader M, Reiss A et al. Bupropion hydrochloride in attention deficit disorder with hyperactivity.J Am Acad Child Adolesc Psychiatry 34: 1314–1321, 1996.CrossRefGoogle Scholar
  159. 159.
    Spencer T, Biederman J, Steingard R, Wilens T. Bupropion exacerbates tics in children with attention-deficit hyperactivity disorder and Tourette’s syndrome.J Am Acad Child Adolesc Psychiatry 32: 211–214, 1993.PubMedCrossRefGoogle Scholar
  160. 160.
    Belson MG, Kelley TR. Bupropion exposures: clinical manifestations and medical outcome.J Emerg Med 23: 223–230, 2002.PubMedCrossRefGoogle Scholar
  161. 161.
    Buitelaar JK, van der Gaag RJ, Swaab-Bameveld H, Kuiper M. Pindolol and methylphenidate in children with attention-deficit hyperactivity disorder: clinical efficacy and side-effects.J Child Psychol Psychiatry 37: 587–595, 1996.PubMedCrossRefGoogle Scholar
  162. 162.
    Feigin A, Kurlan R, McDermott MP, Beach J, Dimitsapulos T, Brower CA et al. A controlled trial of deprenyl in children with Tourette’s syndrome and attention deficit hyperactivity disorder.Neurology 46: 965–968, 1996.PubMedCrossRefGoogle Scholar
  163. 163.
    Hunt RD, Minderaa RB, Cohen DJ. Clonidine benefits children with attention deficit disorder and hyperactivity: report of a double-blind placebo-crossover therapeutic trial.J Am Acad Child Adolesc Psychiatry 24: 617–629, 1985.CrossRefGoogle Scholar
  164. 164.
    Connor DF, Barkery RA, Davis HT. A pilot study of methylphenidate, clonidine, or the combination in ADHD comorbid with aggressive oppositional defiant or conduct disorder.Clin Pediatr 39: 15–25, 2000.CrossRefGoogle Scholar
  165. 165.
    Rapport MD, Denney C, DuPaul GJ, Gardener M. Attention deficit disorder and methylphenidate: normalization rates, clinical effectiveness, and response prediction in 76 children.J Am Acad Child Adolesc Psychiatry 33: 882–893, 1994.PubMedCrossRefGoogle Scholar
  166. 166.
    Hunt RD, Amsten AFT, Asbell MD. An open trial of guanfacine in phe nidatef or attention deficit hyperactivity disorder.J Am Acad Child Adolesc Psychiatry 34: 50–54, 1995.PubMedCrossRefGoogle Scholar
  167. 167.
    Horrigan JP, Bamhill LJ. Guanfacine for treatment of attention-deficit hyperactivity disorder in boys.J Child Adolesc Psychopharmacol 5: 215–223, 1995.CrossRefGoogle Scholar
  168. 168.
    Chappell PB, Riddle MA, Scahill L, Lynch KA, Schultz R, Amsten A et al. Guanfacine treatment of comorbid attention-deficit hyperactivity disorder in Tourette’s syndrome: preliminary clinical experience.J Am Acad Child Adolesc Psychiatry 34: 1140–1146, 1995.PubMedCrossRefGoogle Scholar
  169. 169.
    Solanto MV, Amsten AFT, Catellanos FX. Stimulant drugs and ADHD: basic and clinical neuroscience. New York: Oxford, 2001.Google Scholar
  170. 170.
    Sukhodolsky D, Scahill L, Zhang H, Peterson BS, King RA, Lombroso PJ et al. Disruptive behavior in children with Tourette’ s syndrome: association of ADHD comorbidity, tic severity, and functional impairment.J Am Acad Child Adolesc Psychiatry 42: 98–105, 2003.PubMedCrossRefGoogle Scholar
  171. 171.
    Michelson D, Faries D, Wemicke J, Kelsey D, Kendrick K, Sallee FR et al. Atomoxetine ADHD Study Group. Atomoxetine in the treatment of children and adolescents with attention-deficit/hyperactivity disorder: a randomized, placebo-controlled, dose-response study.Pediatrics 108: E83, 2001.PubMedCrossRefGoogle Scholar
  172. 172.
    Michelson D, Allen AJ, Busner J, Casat C, Dunn D, Kratochvil C et al. Once daily atomoxetine treatment for children and adolescents with attention deficit hyperactivity disorder: a randomized, placebo-controlled study.Am J Psychiatry 159: 1896, 2002.PubMedCrossRefGoogle Scholar
  173. 173.
    Berthier ML, Kulisevsky J, Campos VM. Bipolar disorder in adult patients with Tourette’s syndrome: a clinical study.Biol Psychiatry 43: 364–370, 1998.PubMedCrossRefGoogle Scholar
  174. 174.
    Comings BG, Comings DE. A controlled study of Tourette syndrome. V. Depression and mania.Am J Hum Genet 41: 804–821, 1987.PubMedGoogle Scholar
  175. 175.
    Comings DE, Comings BG. A controlled study of Tourette syndrome. III. Phobias and panic attacks.Am J Hum Genet 41: 761–781, 1987.PubMedGoogle Scholar
  176. 176.
    Comings DE, Comings BG. A controlled family history study of Tourette’s syndrome. III. Affective and other disorders.J Clin Psychiatry 51: 288–291, 1990.PubMedGoogle Scholar
  177. 177.
    Coffey BJ, Biederman J, Smoller JW, Geller DA, Sarin P, Schwartz S et al. Anxiety disorders and tic severity in juveniles with Tourette’s disorder.J Am Acad Child Adolesc Psychiatry 39: 562–568, 2000.PubMedCrossRefGoogle Scholar
  178. 178.
    Coffey BJ, Park KS. Behavioral and emotional aspects of Tourette syndrome.Neurol Clin 15: 277–289, 1997.PubMedCrossRefGoogle Scholar
  179. 179.
    Kerbeshian J, Burd L, Klug MG. Comorbid Tourette’s disorder and bipolar disorder: an etiologic perspective.Am J Psychiatry 152: 1646–1651, 1995.PubMedGoogle Scholar
  180. 180.
    Comings DE. Role of genetic factors in depression based on studies of Tourette syndrome and ADHD probands and their relatives.Am J Med Genet 60: 111–121, 1995.PubMedCrossRefGoogle Scholar
  181. 181.
    Palumbo D, Maughan A, Kurlan R. Hypothesis: III. Tourette syndrome is only one of several causes of a developmental basal ganglia syndrome.Arch Neurol 54: 475–483, 1997.PubMedCrossRefGoogle Scholar
  182. 182.
    King RA, Scahill L. Emotional and behavioral difficulties associated with Tourette syndrome.Adv Neurol 85: 79–88, 2001.PubMedGoogle Scholar
  183. 183.
    Fava M, Rush AJ, Trivedi MH, Nierenberg AA, Thase ME, Sackeim HA et al. Background and rationale for the sequenced treatment alternatives to relieve depression (STAR*D) study.Psychiatr Clin North Am 26: 457–494, 2003.PubMedCrossRefGoogle Scholar
  184. 184.
    Emslie GJ, Mayes TL. Mood disorders in children and adolescents: psychopharmacological treatment.Biol Psychiatry 49: 1082–1090, 2001.PubMedCrossRefGoogle Scholar
  185. 185.
    Sachs GS. Decision tree for the treatment of bipolar disorder.J Clin Psychiatry 64: 35–40, 2003.PubMedCrossRefGoogle Scholar
  186. 186.
    Expert Consensus Guideline Series. Treatment of bipolar disorder.J Clin Psychiatry 57: 3–88, 1996.Google Scholar
  187. 187.
    Gorman JM. Treating generalized anxiety disorder.J Clin Psychiatry 64: 24–29, 2003.PubMedGoogle Scholar
  188. 188.
    Budman CL, Bruun RD, Park KS, Lesser M, Olson M. Explosive outbursts in children with Tourette’s disorder.J Am Acad Child Adoles Psychiatry 39: 1270–1276, 2000.CrossRefGoogle Scholar
  189. 189.
    Freeman RD, Fast DK, Burd L, Kerbeshian J, Robertson MM, Sandor P. An international perspective on Tourette syndrome: selected findings from 3,500 individuals in 22 countries.Dev Med Child Neurol 42: 436–447, 2000.PubMedCrossRefGoogle Scholar
  190. 190.
    Bruun RD, Budman CL. Paroxetine treatment of episodic rages associated with Tourette’s disorder.J Clin Psychiatry 59: 581–584, 1998.PubMedCrossRefGoogle Scholar
  191. 191.
    Research Units on Pediatric Psychopharmacology (RUPP) Autism Network. Risperidone in children with autism for serious behavioral problems.N Engl J Med 347: 314–321, 2002.CrossRefGoogle Scholar
  192. 192.
    Aman MG, De Smedt G, Derivan A, Lyons B, Findling RL. Risperidone Disruptive Behavior Study Group. Double-blind, placebo-controlled study of risperidone for the treatment of disruptive behaviors in children with subaverage intelligence.Am J Psychiatry 159: 1337–1346, 2002.PubMedCrossRefGoogle Scholar
  193. 193.
    Donovan SJ, Stewart JW, Nunes EV, Quitkin FM, Parides M, Daniel W et al. Divalproex treatment for youth with explosive temper and mood lability: a double-blind, placebo-controlled crossover design.Am J Psychiatry 157: 818–820, 2000.PubMedCrossRefGoogle Scholar
  194. 194.
    Lombroso PJ, Scahill L, King RA, Lynch KA, Chappell PB, Peterson BS et al. Risperidone treatment of children and adolescents with chronic tic disorders: a preliminary report.J Am Acad Child Adolesc Psychiatry 34: 1147–1152, 1995.PubMedCrossRefGoogle Scholar
  195. 195.
    McDougle CJ, Goodman WK, Leckman JF, Lee NC, Heninger GR, Price LH. Haloperidol addition in fluvoxamine-refractory obsessive compulsive disorder: a double-blind, placebo-controlled study in patients with and without tics.Arch Gen Psychiatry 51: 302–308, 1994.PubMedCrossRefGoogle Scholar
  196. 196.
    McDougle CJ, Epperson CN, Pelton GH, Wasylink S, Price LH. A double-blind, placebo-controlled study of risperidone addition in serotonin reuptake inhibitor-refractory obsessive-compulsive disorder.Arch Gen Psychiatry 57: 794–801, 2000.PubMedCrossRefGoogle Scholar
  197. 197.
    Figueroa Y, Rosenberg DR, Birmaher B, Keshavan MS. Combination treatment with clomipramine and selective serotonin reuptake inhibitors for obsessive-compulsive disorder in children and adolescents.J Child Adolesc Psychopharmacol 8: 61–67, 1998.PubMedCrossRefGoogle Scholar

Copyright information

© The American Society for Experimental NeuroTherapeutics, Inc. 2006

Authors and Affiliations

  • Lawrence Scahill
    • 1
    • 2
  • Gerald Erenberg
    • 1
  • Cheston M. Berlin
    • 1
  • Cathy Budman
    • 1
  • Barbara J. Coffey
    • 1
  • Joseph Jankovic
    • 1
  • Louise Kiessling
    • 1
  • Robert A. King
    • 1
  • Roger Kurlan
    • 1
  • Anthony Lang
    • 1
  • Jonathan Mink
    • 1
  • Tanya Murphy
    • 1
  • Samual Zinner
    • 1
  • John Walkup
    • 1
  1. 1.Tourette Syndrome Association Medical Advisory Board: Practice CommitteeUSA
  2. 2.Yale Child Study CenterNew Haven

Personalised recommendations